查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肺癌治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按治療類型、適應症、最終用戶和地理位置
市場調查報告書
商品編碼
1389668

肺癌治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按治療類型、適應症、最終用戶和地理位置

Lung Cancer Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, Indication, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 206 Pages | 訂單完成後即時交付

價格

肺癌治療市場預計將從2022年的310.18億美元成長到2030年的804.93億美元；預計2022年至2030年CAGR為12.7%。

標靶治療是一種個人化醫療，是兩種或多種藥物的組合，旨在直接針對癌細胞。消融和化療等療法會破壞健康細胞和受感染細胞，這會影響患者的整體狀況。標靶治療的目的是選擇性地殺死癌細胞，同時保持健康細胞的功能不受阻礙。隨著醫療技術的最新發展，標靶治療用於肺癌治療的關注度顯著增加。科學家正在專注於研究導致癌細胞不受控制生長的肺癌細胞突變。 2021年5月，美國食品藥物管理局批准了Lumakras（sotorasib），這是第一個針對成人非小細胞肺癌患者的治療方法。此療法適用於具有 KRAS G12C 突變且先前至少接受過一種全身性治療的患者。這些公司正在使用 EGFR、ALK、ROS1 和 KRAS 等生物標記來開發標靶療法，幫助檢測癌細胞中的突變類型。因此，公司對標靶療法開發的日益關注，加上人們對其對肺癌患者益處的認知不斷增強，預計將在未來幾年為肺癌治療市場帶來新趨勢。

政府對肺癌篩檢和治療的措施推動了肺癌治療市場的成長

據強生公司發表的文章稱，肺癌是全球癌症死亡的主要原因，而且通常在晚期才被發現。在早期階段，肺癌患者沒有明顯的症狀，因此，在近50%的檢測病例中，癌症已達到轉移階段。針對肺癌的嚴重性，各國政府紛紛推出鼓勵肺癌早期發現、早期篩檢、早期治療的措施。

根據美國預防服務工作小組 (USPSTF) 的數據，年齡在 50-80 歲、每年吸菸 20 包的人，無論是目前吸菸還是在過去 15 年內戒菸，更容易患肺癌在美國。因此，美國預防服務工作小組（USPSTF）建議這些人每年進行低劑量電腦斷層掃描（LDCT）肺癌篩檢，以確保肺癌的早期發現。此外，2022年7月，美國拜登政府推出了一種新模式，旨在改善癌症護理並降低醫療保險服務涵蓋患者的治療成本。

2021 年 7 月，澳洲癌症協會與健康和老年護理部合作，評估澳洲肺癌篩檢計畫的可行性。在獲得積極的可行性評估結果後，2023年5月，澳洲政府衛生和老年護理部宣布2023-2024年投資2.638億美元，用於在全國範圍內實施國家肺癌篩檢計畫國家。透過該計劃，健康和老年護理部重點關注肺癌的預防和早期發現。此外，歐洲衛生聯盟推出的「戰勝癌症計畫」旨在透過專注於肺癌患者的預防、治療和照護來解決整個疾病途徑。

因此，各國政府為肺癌患者的早期發現和適當治療所採取的措施激增，推動了肺癌治療市場的成長。

肺癌治療市場根據治療類型、適應症、最終用戶和地理位置進行分類。肺癌治療市場依疫苗類型分為非侵入性療法和微創療法。微創細分又分為射頻消融、微波消融、熱消融、冷凍消融、化學消融、光動力消融等。肺癌治療市場依適應症分為非小細胞肺癌和小細胞肺癌。依最終用戶分類，市場分為醫院、腫瘤診所、研究中心等。

根據地理位置，市場分為北美、歐洲、亞太地區、中東和非洲以及南美洲和中美洲。北美在肺癌治療市場中佔有最大的市場佔有率。由於吸菸、菸草消費的增加以及工業化導致的空氣污染增加，導致肺癌發生率不斷上升，北美佔據了重要的市場佔有率。美國肺癌治療市場的成長主要是由肺癌病例發病率上升、產品發布和政府措施推動的。肺癌是美國第二常見癌症。根據美國癌症協會的數據，截至 2023 年，美國約有 238,340 名成年人（117,550 名男性和 120,790 名女性）被診斷出患有肺癌；此外，約有 127,070 人（男性 67,160 人，女性 59,910 人）死於此疾病。肺癌佔所有癌症死亡的五分之一，使其成為美國癌症死亡的主要原因。根據同一來源，非小細胞肺癌 (NSCLC) 佔所有肺癌診斷的 81%。因此，該國肺癌發病率的上升推動了美國肺癌治療市場的成長。

公司推出的各種治療肺癌的產品也促進了市場的成長。例如，2021年5月，美國FDA核准Lumakras（sotorasib）作為第一個針對成人非小細胞肺癌患者的標靶治療藥物。這是第一個被批准用於具有 KRAS 突變的腫瘤的標靶治療，據報告，非小細胞肺癌 (NSCLC) 中約有 25% 的突變。此外，2021年5月，美國FDA加速核准amivantamab-vmjw (Rybrevant)，是一種針對錶皮生長因子(EGF)和MET受體的雙特異性抗體，用於治療含有EGFR外顯子20插入的局部晚期或轉移性NSCLC成人患者突變。

根據數位策略辦公室管理的白宮官方網站 Whitehouse.gov 於 2023 年 5 月發布的報告，社區癌症中心協會 (ACCC) 與阿斯特捷利康建立了合作夥伴關係，以開發和實施透過「農村阿巴拉契亞肺癌篩檢計畫”，以人為本和永續的方法來推動美國農村地區的肺癌篩檢。阿巴拉契亞地區（包括整個西維吉尼亞州和其他 12 個州的部分地區）的癌症死亡率比美國其他地區高 10%。該措施旨在將肺癌的五年存活率提高一倍。這些措施正在促進美國肺癌治療市場的成長。

ClinicalTrails.com、疾病管制與預防中心 (CDC)、食品藥物管理局 (FDA) 以及美國預防服務工作組 (USPSTF) 是準備肺癌報告時參考的幾個關鍵的主要和次要來源治療市場。

目錄

第 1 章：簡介

  • Insight Partners 研究報告指南
  • 市場區隔

第 2 章：執行摘要

  • 肺癌治療市場（依地理位置）

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：肺癌治療市場格局

  • 概述
  • PEST分析
    • 全球PEST分析

第 5 章：肺癌治療市場 - 主要產業動態

  • 市場促進因素：
    • 肺癌病例增加
    • 政府針對肺癌篩檢和治療的舉措
  • 市場限制
    • 肺癌治療費用高昂
  • 市場機會
    • 臨床試驗中肺癌治療的數量不斷增加
  • 未來的趨勢
    • 標靶治療的需求不斷成長
  • 影響分析：

第 6 章：肺癌治療市場 - 全球市場分析

  • 肺癌治療市場收入，2020 - 2030

第 7 章：全球肺癌治療市場 - 2030 年收入和預測 - 按治療類型

  • 概述
  • 2022 年和 2030 年按治療類型分類的肺癌治療市場收入佔有率 (%)
  • 非侵入性治療
  • 微創

第 8 章：全球肺癌治療市場 - 2030 年收入和預測 - 按適應症

  • 概述
  • 2022 年和 2030 年按適應症分類的肺癌治療市場收入佔有率 (%)
  • 非小細胞肺癌
  • 小細胞肺癌

第 9 章：全球肺癌治療市場 - 收入和 2030 年預測 - 按最終用戶

  • 概述
  • 2022 年和 2030 年按最終用戶分類的肺癌治療市場收入佔有率 (%)
  • 醫院
  • 腫瘤科診所
  • 研究中心
  • 其他

第 10 章：肺癌治療市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 東南亞
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：肺癌治療市場 - 產業格局

  • 概述
  • 肺癌治療市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 12 章：公司簡介

  • Medtronic Plc
  • RF Medical Co Ltd
  • Johnson & Johnson
  • Merck KGaA
  • Sun Pharmaceutical Industries Ltd
  • Bioventus Inc
  • Olympus Corp
  • Meiji Seika Pharma Co Ltd
  • Advanz Pharma Corp

第 13 章：附錄

  • 關於我們
  • 專業術語
Product Code: TIPRE00030093

The lung cancer therapy market is expected to grow from US$ 31.018 billion in 2022 to US$ 80.493 billion by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030.

Targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells. In May 2021, the US Food and Drug Administration approved Lumakras (sotorasib), the first treatment for adult non-small cell lung cancer patients. This therapy is given to patients who have KRAS G12C mutation and have received at least one prior systemic therapy. The companies are using biomarkers such as EGFR, ALK, ROS1, and KRAS to develop targeted therapies, which help detect the type of mutation in the cancerous cells. Thus, the increasing focus of companies on the development of targeted therapies, coupled with the growing awareness about their benefits to lung cancer patients, is expected to bring new trends in the lung cancer therapy market in the coming years.

Government Initiatives for Screening and Treatment of Lung Cancer drives the growth the Lung Cancer Therapy Market

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer.

As per United States Preventive Services Task Force (USPSTF), people from the age range of 50-80 with a smoking history of 20 packs per year, either presently smoking or having quit within the last 15 years, are more susceptible to developing lung cancer in the US. Hence, the United States Preventive Services Task Force (USPSTF) recommends these people undergo low-dose computed tomography (LDCT) screening for lung cancer every year to ensure the early detection of lung cancer. In addition, in July 2022, the Biden Administration in the US introduced a new model that aims to improve cancer care and lower the treatment cost for patients who are covered under Medicare services.

In July 2021, Cancer Australia partnered with the Department of Health and Aged Care to evaluate the feasibility of a lung cancer screening program in Australia. After obtaining positive results of the feasibility assessment, in May 2023, the Department of Health and Aged Care, the Government of Australia, declared an investment of US$ 263.8 million for 2023-2024 for the implementation of the National Lung Cancer Screening Program across the country. Through this program, the Department of Health and Aged Care focuses on the prevention and early detection of lung cancer. Further, the Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients.

Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the lung cancer therapy market.

The lung cancer therapy market is divided on the basis of therapy type, indication, end user, and geography. The lung cancer therapy market, by vaccine type, is bifurcated into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. The lung cancer therapy market, by indication, is segmented into non-small cell lung cancer and small cell lung cancer. The market, by end user, is segmented into hospitals, oncology clinics, research centers, and others.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the lung cancer therapy market. North America accounts for a significant market share owing to the growing incidences of lung cancer cases due to increase in smoking, consumption of tobacco, and increase in air pollution due to industrialization. The growth of the lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.

Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. For instance, in May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy that is approved for tumors with KRAS mutation, which reports ~25% of mutations in non-small cell lung cancer (NSCLC). Moreover, in May 2021, the US FDA granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.

As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca entered into a partnership for the development and implementation of person-centered and sustainable approaches to drive lung cancer screening in rural America through "Rural Appalachian Lung Cancer Screening Initiative." The cancer mortality rate in the Appalachian region, including all of West Virginia and a few parts of 12 other states, is 10% higher than that of the rest of the US. This initiative aims to double the five-year survival rate for lung cancer. Such initiatives are contributing to the growth of the lung cancer therapy market in the US.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and United States Preventive Services Task Force (USPSTF) are a few key primary and secondary sources referred to while preparing the report on the lung cancer therapy market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the lung cancer therapy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the lung cancer therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the lung cancer therapy market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Lung Cancer Therapy Market, by Geography

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Lung Cancer Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Global PEST Analysis

5. Lung Cancer Therapy Market - Key Industry Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Increase in Cases of Lung Cancer
    • 5.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Lung Cancer Therapy
  • 5.3 Market Opportunities
    • 5.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
  • 5.4 Future Trends
    • 5.4.1 Growing Demand for Targeted Therapy
  • 5.5 Impact Analysis:

6. Lung Cancer Therapy Market - Global Market Analysis

  • 6.1 Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

7. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

  • 7.1 Overview
  • 7.2 Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
  • 7.3 Non-Invasive Therapy
    • 7.3.1 Overview
    • 7.3.2 Non-Invasive Therapy: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Minimally Invasive
    • 7.4.1 Overview
    • 7.4.2 Minimally Invasive: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.1 Global: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

8. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

  • 8.1 Overview
  • 8.2 Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
  • 8.3 Non-Small Cell Lung Cancer
    • 8.3.1 Overview
    • 8.3.2 Non-Small Cell Lung Cancer: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Small Cell Lung Cancer
    • 8.4.1 Overview
    • 8.4.2 Small Cell Lung Cancer: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Oncology Clinics
    • 9.4.1 Overview
    • 9.4.2 Oncology Clinics: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Research Centers
    • 9.5.1 Overview
    • 9.5.2 Research Centers: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. Lung Cancer Therapy Market - Geographical Analysis

  • 10.1 North America Lung Cancer Therapy Market, Revenue and Forecast To 2030
    • 10.1.1 Overview
    • 10.1.2 North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.1.3 North America: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
      • 10.1.3.1 North America: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    • 10.1.4 North America: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    • 10.1.5 North America: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    • 10.1.6 North America Lung Cancer Therapy Market, by Country
      • 10.1.6.1 US
        • 10.1.6.1.1 Overview
        • 10.1.6.1.2 US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.1.3 US: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.6.1.3.1 US: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.1.6.1.4 US: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.6.1.5 US: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.1.6.2 Canada
        • 10.1.6.2.1 Overview
        • 10.1.6.2.2 Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.2.3 Canada: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.6.2.3.1 Canada: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.1.6.2.4 Canada: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.6.2.5 Canada: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.1.6.3 Mexico
        • 10.1.6.3.1 Overview
        • 10.1.6.3.2 Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.3.3 Mexico: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.6.3.3.1 Mexico: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.1.6.3.4 Mexico: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.6.3.5 Mexico: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  • 10.2 Europe Lung Cancer Therapy Market, Revenue and Forecast to 2030
    • 10.2.1 Overview
    • 10.2.2 Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.2.3 Europe: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
      • 10.2.3.1 Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    • 10.2.4 Europe: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    • 10.2.5 Europe: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    • 10.2.6 Europe Lung Cancer Therapy Market, by Country
      • 10.2.6.1 UK
        • 10.2.6.1.1 Overview
        • 10.2.6.1.2 UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.1.3 UK: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.6.1.3.1 UK: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.2.6.1.4 UK: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.6.1.5 UK: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.2 Germany
        • 10.2.6.2.1 Overview
        • 10.2.6.2.2 Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.2.3 Germany: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.6.2.3.1 Germany: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.2.6.2.4 Germany: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.6.2.5 Germany: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.3 France
        • 10.2.6.3.1 Overview
        • 10.2.6.3.2 France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.3.3 France: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.6.3.3.1 France: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.2.6.3.4 France: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.6.3.5 France: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.4 Italy
        • 10.2.6.4.1 Overview
        • 10.2.6.4.2 Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.4.3 Italy: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.6.4.3.1 Italy: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.2.6.4.4 Italy: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.6.4.5 Italy: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.5 Spain
        • 10.2.6.5.1 Overview
        • 10.2.6.5.2 Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.5.3 Spain: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.6.5.3.1 Spain: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.2.6.5.4 Spain: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.6.5.5 Spain: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.6 Russia
        • 10.2.6.6.1 Overview
        • 10.2.6.6.2 Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.6.3 Russia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.6.6.3.1 Russia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.2.6.6.4 Russia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.6.6.5 Russia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.7 Rest of Europe
        • 10.2.6.7.1 Overview
        • 10.2.6.7.2 Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.7.3 Rest of Europe: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.6.7.3.1 Rest of Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.2.6.7.4 Rest of Europe: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.6.7.5 Rest of Europe: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  • 10.3 Asia Pacific Lung Cancer Therapy Market, Revenue and Forecast to 2030
    • 10.3.1 Overview
    • 10.3.2 Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.3.3 Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
      • 10.3.3.1 Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    • 10.3.4 Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    • 10.3.5 Asia Pacific: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    • 10.3.6 Asia Pacific Lung Cancer Therapy Market, by Country
      • 10.3.6.1 China
        • 10.3.6.1.1 Overview
        • 10.3.6.1.2 China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.1.3 China: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.1.3.1 China: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.1.4 China: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.1.5 China: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.2 Japan
        • 10.3.6.2.1 Overview
        • 10.3.6.2.2 Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.2.3 Japan: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.2.3.1 Japan: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.2.4 Japan: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.2.5 Japan: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.3 India
        • 10.3.6.3.1 Overview
        • 10.3.6.3.2 India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.3.3 India: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.3.3.1 India: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.3.4 India: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.3.5 India: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.4 Australia
        • 10.3.6.4.1 Overview
        • 10.3.6.4.2 Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.4.3 Australia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.4.3.1 Australia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.4.4 Australia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.4.5 Australia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.5 South Korea
        • 10.3.6.5.1 Overview
        • 10.3.6.5.2 South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.5.3 South Korea: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.5.3.1 South Korea: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.5.4 South Korea: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.5.5 South Korea: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.6 Southeast Asia
        • 10.3.6.6.1 Overview
        • 10.3.6.6.2 Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.3 Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.6.3.1 Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.6.4 Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.6.5 Southeast Asia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
        • 10.3.6.6.6 Singapore
        • 10.3.6.6.6.1 Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.6.2 Singapore: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.6.6.2.1 Singapore: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.6.6.3 Singapore: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.6.6.4 Singapore: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
        • 10.3.6.6.7 Malaysia
        • 10.3.6.6.7.1 Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.7.2 Malaysia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.6.7.2.1 Malaysia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.6.7.3 Malaysia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.6.7.4 Malaysia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
        • 10.3.6.6.8 Indonesia
        • 10.3.6.6.8.1 Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.8.2 Indonesia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.6.8.2.1 Indonesia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.6.8.3 Indonesia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.6.8.4 Indonesia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
        • 10.3.6.6.9 Vietnam
        • 10.3.6.6.9.1 Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.9.2 Vietnam: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.6.9.2.1 Vietnam: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.6.9.3 Vietnam: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.6.9.4 Vietnam: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
        • 10.3.6.6.10 Cambodia
        • 10.3.6.6.10.1 Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.10.2 Cambodia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.6.10.2.1 Cambodia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.6.10.3 Cambodia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.6.10.4 Cambodia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
        • 10.3.6.6.11 Philippines
        • 10.3.6.6.11.1 Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.11.2 Philippines: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.6.11.2.1 Philippines: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.6.11.3 Philippines: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.6.11.4 Philippines: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
        • 10.3.6.6.12 Rest of Southeast Asia
        • 10.3.6.6.12.1 Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.12.2 Rest of Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.6.12.2.1 Rest of Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.6.12.3 Rest of Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.6.12.4 Rest of Southeast Asia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.7 Rest of Asia Pacific
        • 10.3.6.7.1 Overview
        • 10.3.6.7.2 Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.7.3 Rest of Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.6.7.3.1 Rest of Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.3.6.7.4 Rest of Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.6.7.5 Rest of Asia Pacific: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  • 10.4 Middle East & Africa Lung Cancer Therapy Market, Revenue and Forecast to 2030
    • 10.4.1 Overview
    • 10.4.2 Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.4.3 Middle East & Africa: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
      • 10.4.3.1 Middle East & Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    • 10.4.4 Middle East & Africa: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    • 10.4.5 Middle East & Africa: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.1 Middle East & Africa Lung Cancer Therapy Market, by Country
      • 10.4.5.2 Saudi Arabia
        • 10.4.5.2.1 Overview
        • 10.4.5.2.2 Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.2.3 Saudi Arabia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.2.3.1 Saudi Arabia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.4.5.2.4 Saudi Arabia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.2.5 Saudi Arabia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.3 South Africa
        • 10.4.5.3.1 Overview
        • 10.4.5.3.2 South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.3.3 South Africa: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.3.3.1 South Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.4.5.3.4 South Africa: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.3.5 South Africa: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.4 UAE
        • 10.4.5.4.1 Overview
        • 10.4.5.4.2 UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.4.3 UAE: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.4.3.1 UAE: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.4.5.4.4 UAE: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.4.5 UAE: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.5 Rest of Middle East Africa
        • 10.4.5.5.1 Overview
        • 10.4.5.5.2 Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.5.3 Rest of Middle East Africa: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.5.3.1 Rest of Middle East Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.4.5.5.4 Rest of Middle East Africa: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.5.5 Rest of Middle East Africa: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  • 10.5 South & Central America Lung Cancer Therapy Market, Revenue and Forecast to 2030
    • 10.5.1 Overview
    • 10.5.2 South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.5.3 South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
      • 10.5.3.1 South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    • 10.5.4 South & Central America: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    • 10.5.5 South & Central America: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    • 10.5.6 South & Central America Lung Cancer Therapy Market, by Country
      • 10.5.6.1 Brazil
        • 10.5.6.1.1 Overview
        • 10.5.6.1.2 Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.1.3 Brazil: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.5.6.1.3.1 Brazil: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.5.6.1.4 Brazil: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.5.6.1.5 Brazil: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.5.6.2 Argentina
        • 10.5.6.2.1 Overview
        • 10.5.6.2.2 Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.2.3 Argentina: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.5.6.2.3.1 Argentina: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.5.6.2.4 Argentina: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.5.6.2.5 Argentina: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
      • 10.5.6.3 Rest of South & Central America
        • 10.5.6.3.1 Overview
        • 10.5.6.3.2 Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.3.3 Rest of South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.5.6.3.3.1 Rest of South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
        • 10.5.6.3.4 Rest of South & Central America: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.5.6.3.5 Rest of South & Central America: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)

11. Lung Cancer Therapy Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Lung Cancer Therapy Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Medtronic Plc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 RF Medical Co Ltd
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Merck KGaA
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Sun Pharmaceutical Industries Ltd
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Bioventus Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Olympus Corp
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Meiji Seika Pharma Co Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Advanz Pharma Corp
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Lung Cancer Therapy Market Segmentation
  • Table 2. Global Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America Lung Cancer Therapy Market, by Therapy Type- Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 5. North America Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. North America Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. US Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. US Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 9. US Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 10. US Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Canada Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Canada Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Canada Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Mexico Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Mexico Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Mexico Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Mexico Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Europe Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. Europe Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. UK Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. UK Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 25. UK Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 26. UK Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Germany Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Germany Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Germany Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Germany Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 31. France Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. France Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 33. France Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 34. France Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 35. Italy Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. Italy Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 37. Italy Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 38. Italy Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 39. Spain Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. Spain Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 41. Spain Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 42. Spain Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 43. Russia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 44. Russia Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 45. Russia Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 46. Russia Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 47. Rest of Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 48. Rest of Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
  • Table 49. Rest of Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
  • Table 50. Rest of Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 51. Asia Pacific Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 52. Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 53. Asia Pacific Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 54. Asia Pacific Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 55. China Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 56. China Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 57. China Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 58. China Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 59. Japan Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 60. Japan Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 61. Japan Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 62. Japan Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 63. India Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 64. India Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 65. India Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 66. India Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 67. Australia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 68. Australia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 69. Australia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 70. Australia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 71. South Korea Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 72. South Korea Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 73. South Korea Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 74. South Korea Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 75. Southeast Asia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 76. Southeast Asia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 77. Southeast Asia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 78. Southeast Asia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 79. Singapore Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 80. Singapore Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 81. Singapore Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 82. Singapore Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 83. Malaysia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 84. Malaysia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 85. Malaysia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 86. Malaysia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 87. Indonesia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 88. Indonesia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 89. Indonesia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 90. Indonesia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 91. Vietnam Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 92. Vietnam Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 93. Vietnam Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 94. Vietnam Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 95. Cambodia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 96. Cambodia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 97. Cambodia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 98. Cambodia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 99. Philippines Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 100. Philippines Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 101. Philippines Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 102. Philippines Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 103. Rest of Southeast Asia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 104. Rest of Southeast Asia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 105. Rest of Southeast Asia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 106. Rest of Southeast Asia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 107. Rest of Asia Pacific Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 108. Rest of Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 109. Rest of Asia Pacific Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 110. Rest of Asia Pacific Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 111. Middle East & Africa Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 112. Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 113. Middle East & Africa Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 114. Middle East & Africa Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 115. Saudi Arabia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 116. Saudi Arabia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 117. Saudi Arabia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 118. Saudi Arabia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 119. South Africa Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 120. South Africa Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 121. South Africa Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 122. South Africa Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 123. UAE Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 124. UAE Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 125. UAE Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 126. UAE Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 127. Rest of Middle East Africa Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 128. Rest of Middle East Africa Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 129. Rest of Middle East Africa Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 130. Rest of Middle East Africa Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 131. South & Central America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 132. South & Central America Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 133. South & Central America Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 134. South & Central America Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 135. Brazil Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 136. Brazil Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 137. Brazil Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 138. Brazil Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 139. Argentina Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 140. Argentina Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 141. Argentina Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 142. Argentina Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 143. Rest of South & Central America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 144. Rest of South & Central America Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
  • Table 145. Rest of South & Central America Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 146. Rest of South & Central America Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 147. Recent Inorganic Growth Strategies in the Lung Cancer Therapy Market
  • Table 148. Recent Organic Growth Strategies in Lung Cancer Therapy Market
  • Table 149. Glossary of Terms, Lung Cancer Therapy Market

List Of Figures

  • Figure 1. Lung Cancer Therapy Market Segmentation, By Geography
  • Figure 2. Global - PEST Analysis
  • Figure 3. Lung Cancer Therapy Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030
  • Figure 6. Lung Cancer Therapy Market Revenue, Geography (US$ Mn), 2022 - 2030
  • Figure 7. Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
  • Figure 8. Non-Invasive Therapy: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Minimally Invasive: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
  • Figure 11. Non-Small Cell Lung Cancer: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Small Cell Lung Cancer: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
  • Figure 14. Hospitals: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Oncology Clinics: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Research Centers: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Others: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. North America: Lung Cancer Therapy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 19. North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 20. North America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 21. US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Europe Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 25. Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Europe Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 27. UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 29. France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 32. Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 33. Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 34. Asia Pacific Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 35. Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 36. Asia Pacific Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 37. China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 38. Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 39. India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 40. Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 41. South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 42. Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 43. Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 44. Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 45. Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 46. Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 47. Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 48. Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 49. Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 50. Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 51. Middle East & Africa Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 52. Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 53. Middle East & Africa Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 54. Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 55. South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 56. UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 57. Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 58. South & Central America Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 59. South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 60. South & Central America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 61. Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 62. Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 63. Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 64. Growth Strategies in Lung Cancer Therapy Market